GILEAD | Medical Information

Vemlidy® (tenofovir alafenamide) Crushing or Splitting Tablets

This document is in response to your request for information regarding the crushing or splitting of Vemlidy® (tenofovir alafenamide [TAF]) tablets.

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.

Product Labeling[1]

There is no information in the TAF product label regarding the crushing or splitting of TAF tablets; therefore, it is not recommended that FTC/TAF be administered as a crushed or split tablet.

TAF has a solubility of 4.7 mg per mL in water at 20°C.

Available Data on Crushing or Splitting TAF Tablets

Gilead Data

TAF tablets are not enteric coated and do not possess a sustained-release mechanism. There are no studies evaluating the pharmacokinetic parameters (eg, oral bioavailability) of the crushed TAF tablet dispersed into a liquid medium (eg, milk, water, or juice) vs those of the whole tablet.

Similarly, the splitting of TAF tablets has not been studied and it is not recommended. There are no studies evaluating the pharmacokinetics of a split TAF tablet vs those of a whole tablet.

Non-Gilead Data

A literature search was conducted in Ovid MEDLINE and Embase databases for studies published through October 13, 2025, using the search terms Vemlidy, tenofovir alafenamide, and cutting, crushing, splitting tablets and related search terms. While there are data on crushing TAF in an HIV setting, no relevant citations were found for use in HBV.

Reference

1. Enclosed. Gilead Sciences Inc, VEMLIDY® (tenofovir alafenamide) tablets, for oral use. U.S. Prescribing Information. Foster City, CA.

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Vemlidy US Prescribing Information available at: www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vemlidy/vemlidy_pi.

Follow Up

For any additional questions, please contact Gilead Medical Information at:

☎1-866-MEDI-GSI (1-866-633-4474) or http://www.askgileadmedical.com/

Adverse Event Reporting

Please report all adverse events to:

Gilead Pharmacovigilance and Epidemiology ☎ 1-800-445-3235, option 3

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact privacy@gilead.com.